Market closed
Protagonist Therapeutics/$PTGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Ticker
$PTGX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
126
Website
PTGX Metrics
BasicAdvanced
$3.5B
13.63
$4.23
2.21
-
Price and volume
Market cap
$3.5B
Beta
2.21
52-week high
$60.60
52-week low
$24.22
Average daily volume
1.1M
Financial strength
Current ratio
12.482
Quick ratio
12.393
Long term debt to equity
1.534
Total debt to equity
1.609
Management effectiveness
Return on assets (TTM)
28.66%
Return on equity (TTM)
54.39%
Valuation
Price to earnings (TTM)
13.629
Price to revenue (TTM)
8.17
Price to book
5.21
Price to tangible book (TTM)
5.21
Price to free cash flow (TTM)
19.417
Growth
Revenue change (TTM)
624.06%
Earnings per share change (TTM)
-404.11%
3-year revenue growth (CAGR)
151.35%
3-year earnings per share growth (CAGR)
15.99%
What the Analysts think about PTGX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
PTGX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PTGX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PTGX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Protagonist Therapeutics stock?
Protagonist Therapeutics (PTGX) has a market cap of $3.5B as of March 14, 2025.
What is the P/E ratio for Protagonist Therapeutics stock?
The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 13.63 as of March 14, 2025.
Does Protagonist Therapeutics stock pay dividends?
No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Protagonist Therapeutics dividend payment date?
Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) has a beta rating of 2.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
